TRAX — First Tracks Biotherapeutics Inc
$44.05+2.11%
Last close: · regular session
Last 38 sessions
TRAX closed at $44.05 (+2.11%) on Oct 23, 2026. Recent offering filing (S-1, Oct 2026). Float: 31.1M shares. Latest SEC filing: S-1 on Oct 26, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for TRAX in the TickerWise workspace.
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 104
- Website: https://www.firsttracksbio.com
Latest SEC filings for TRAX
Latest TRAX news
- First Tracks Biotherapeutics announces $200M private placement Read article
- First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor Read article
- First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday Read article
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.